<DOC>
	<DOCNO>NCT01438229</DOCNO>
	<brief_summary>This prospective , multicenter , feasibility study safety efficacy renal denervation patient resistant hypertension .</brief_summary>
	<brief_title>Safety Efficacy Study Renal Artery Ablation Resistant Hypertension Patients</brief_title>
	<detailed_description>Demonstrate safety efficacy St. Jude Medical Radiofrequency ( RF ) Renal Denervation System treatment patient resistant hypertension . Safety Marker - All adverse event Efficacy Marker - Office blood pressure</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Office systolic blood pressure remain ≥160 mmHg ( ≥150 mmHg patient type 2 diabetes ) despite stable use ≥3 antihypertensive medication concurrently maximally tolerated dos , one diuretic , minimum 14 day prior enrollment Age ≥18 ≤80 year old Able willing provide write informed consent participate study Able willing comply require followup schedule Prior renal artery intervention ( balloon angioplasty stenting ) Evidence renal artery atherosclerosis ( define stenotic severity &gt; 30 % ) either renal artery Multiple main renal artery either kidney Main renal artery &lt; 4 mm diameter &lt; 20 mm length eGFR &lt; 45 mL/min per 1.73 m2 use MDRD formula Type 1 diabetes Renovascular hypertension hypertension secondary renal disorder ( glomerulonephritis , polycystic kidney disease , endstage renal failure ) Others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Catheter-based renal artery ablation</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Resistant Conventional Therapy</keyword>
</DOC>